Coronavirus vaccine won't be ready in time for the second wave, says Oxford's Sir John Bell

A CORONAVIRUS vaccine won’t be ready in time for the second wave, the Government’s leading life sciences adviser has warned.

Sir John Bell, 68, who sits on the UK’s vaccine taskforce and is also Oxford University’s regius professor of medicine, has warned that while the majority of vaccines take around eight years to develop, experts have only been working on a Covid-19 one for “just eight months”.

⚠️ Read our coronavirus live blog for the latest news & updates

The comments come after Oxford University restarted its key clinical trial for a coronavirus vaccine – after it was halted when a volunteer suffered a suspected serious adverse reaction.

The Medicines Health Regulatory Authority (MHRA) today confirmed that it was safe to resume trials in a boost to the UK's efforts to secure a Covid-19 vaccine.

Recently, the vaccine progressed to Phase 3 testing, which meant it was able to be trialled on large numbers of patients across different geographies.

By last week, around 30,000 people in the UK, the US, Brazil and South Africa had taken part, in a tie-up with pharma giant AstraZeneca.

With the testing now back on, a vaccine could possibly be ready by the end of the year.

But Sir John told The Daily Telegraph: “We’re not going to beat the second wave now.”

Health Secretary Matt Hancock told LBC last week that AstraZeneca had already started to produce doses of the vaccine.

“We’ve got 30 million doses already contracted for with AstraZeneca,” Hancock had said.

Sir John warned: “We’re probably right at the front end of the second wave now, but a vaccine might arrive towards the end of the second wave".

"We’re probably about three to four months ahead of anybody else with a practical vaccine”.

AstraZeneca, the pharmaceutical giant working alongside the University,also said the suspension is "routine" and is to be expected in large and significant vaccination trials.

Details of the "potentially unexplained illness" reportedly suffered by the volunteer remain unclear.

The New York Times reports that the volunteer was diagnosed with transverse myelitis, an inflammatory syndrome affecting the spinal cord, though this has not been confirmed.

It comes as a big boost to the UK's most high profile vaccine trial – which previously has shown strong immune responses in volunteers.

No unexpected adverse reactions were recorded prior to Tuesday, although more than half of 1,000 participants reported mild or moderate side effects including headaches and muscle pain.

Oxford's vaccine is one of two currently being developed in the UK, alongside Imperial College London.

Late last month, AstraZeneca began recruiting 30,000 people in the US for its largest study of the vaccine.

It also is testing the vaccine in thousands of people in the UK, and in smaller studies in Brazil and South Africa.




Source: Read Full Article